Epigenetic causes of apoptosis resistance in cutaneous T-cell lymphomas

Journal of Investigative Dermatology

Volumn 130, Issue 4, 2010, Pages 922-924

  Contassot, Emmanuel ^a   French, Lars E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; FAS ANTIGEN; ROMIDEPSIN; VORINOSTAT;

APOPTOSIS; CELL DEATH; CUTANEOUS T CELL LYMPHOMA; EPIGENETICS; GENE SILENCING; HOMEOSTASIS; HUMAN; METHYLATION; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 77949496806     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.427     Document Type: Note

References (24)

1. Batty N, Malouf GG, Issa JP (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280:192-200
2. Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321:209-213
3. Braun FK, Fecker LF, Schwarz C et al. (2007) Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 127:2425-2437
4. Bullani RR, Wehrli P, Viard-Leveugle I et al. (2002) Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res 12:263-270
5. Contassot E, Kerl K, Roques S et al. (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780-4787
6. Costello JF, Fruhwald MC, Smiraglia DJ et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138
7. + T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol 143:1205-1210
8. Dereure O, Levi E, Vonderheid EC et al. (2002) Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 118:949-956
9. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286-298
10. Fenaux P, Raza A, Mufti GJ et al. (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 109:4158-4163
11. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261-282
12. Gazin C, Wajapeyee N, Gobeil S et al. (2007) An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449:1073-1077
13. Holliday R, Grigg GW (1993) DNA methylation and mutation. Mutat Res 285:61-67
14. Jones CL, Wain EM, Chu C-C et al. (2010) Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation. J Invest Dermatol 130:1116-1125
15. Nagasawa T, Takakuwa T, Takayama H et al. (2004) Fas gene mutations in mycosis fungoides: analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology 67:130-134
16. Olsen EA, Kim YH, Kuzel TM et al. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25:3109-3115
17. Petak I, Danam RP, Tillman DM et al. (2003) Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10:211-217
18. Piekarz RL, Frye R, Turner M et al. (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous t-cell lymphoma. J Clin Oncol 27:5410-5417
19. Rieux-Laucat F, Le Deist F, Hivroz C et al. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349
20. Scarisbrick JJ, Woolford AJ, Calonje E et al. (2002) Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome. J Invest Dermatol 118:493-499
21. van Doorn R, Dijkman R, Vermeer MH et al. (2002) A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62:5389-5392
22. Wu J, Nihal M, Siddiqui J et al. (2009) Low FAS/ CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 129:1165-1173
23. Zhang CL, Kamarashev J, Qin JZ et al. (2003) Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 200:249-254
24. Zoi-Toli O, Vermeer MH, De Vries E et al. (2000) Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313-319